Phase III trial comparing antibody-drug conjugate (ADC) SAR408701 with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) failing chemotherapy and immunotherapy.

被引：0
|
作者：
Johnson, Melissa Lynne
Chadjaa, Mustapha
Yoruk, Semra
Besse, Benjamin
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Sanofi R&d, Vitry Sur Seine, France
[3] Sanofi R&d, Istanbul, Turkey
[4] Gustave Roussy Univ Paris Sud, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9625
引用
收藏
页数：2
相关论文
共 50 条
  • [1] First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC).
    Gazzah, Anas
    Cousin, Sophie
    Boni, Valentina
    Ricordel, Charles
    Kim, Tae Min
    Kim, Jin-Soo
    Helissey, Carole
    Gardeazabal, Itziar
    Chadjaa, Mustapha
    Allard, Aurore
    Yoruk, Semra
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
    Gazzah, Anas
    Ricordel, Charles
    Cousin, Sophie
    Cho, Byoung Chul
    Calvo, Emiliano
    Kim, Tae Min
    Helissey, Carole
    Kim, Jin-Soo
    Vieito, Maria
    Boni, Valentina
    Chadjaa, Mustapha
    Hospitel, Marie
    Yoruk, Semra
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)
    Sakai, H.
    Nishio, M.
    Hida, T.
    Nakagawa, K.
    Nogami, N.
    Atagi, S.
    Takahashi, T.
    Nokihara, H.
    Saka, H.
    Takenoyama, M.
    Fujita, S.
    Tanaka, H.
    Takeda, K.
    Satouchi, M.
    Isobe, H.
    Maemondo, M.
    Goto, K.
    Hirashima, T.
    Minato, K.
    Tamura, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S111
  • [4] Maintenance chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC)
    Belalcazar, A.
    Santos, E. S.
    Gomez, J. E.
    Lopez, E.
    Raez, L. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
    De Miguel, M.
    Yamamoto, N.
    Raimbourg, J.
    Cho, B. C.
    Gottfried, M.
    Stemmer, S. M.
    Goldman, J. W.
    Blaney, M. E.
    Jennaro, T.
    Vasilopoulos, A.
    Li, R. R.
    Freise, K. J.
    Aristide, M. R. Neagu
    Morrison-Thiele, G.
    Hunter, Z. N.
    Burns, M.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2024, 35 : S805 - S806
  • [6] Biomarker analysis from Phase 1/2 study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)
    Gazzah, Anas
    Lee, Joon Sang
    Wang, Emma
    Ternes, Nils
    Wang, Hong
    Boitier, Eric
    lartigau, AuDe
    Chadjaa, Mustapha
    Dib, Colette
    Muzard, Gaelle
    Valence, Sandrine
    Remaury, Anne
    Palu, Cintia C.
    Bauchet, Anne-Laure
    CANCER RESEARCH, 2023, 83 (08)
  • [7] Phase II Studies of Nivolumab in Patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small-Cell Lung Cancer (NSCLC)
    Nakagawa, Kazuhiko u
    Nishio, Makoto
    Hida, Toyoaki
    Sakai, Hiroshi
    Nogami, Naoyuki
    Atagi, Shinji
    Takahashi, Toshiaki
    Nokihara, Hiroshi
    Saka, Hideo
    Takenoyama, Mitsuhiro
    Fujita, Shiro
    Tanaka, Hiroshi
    Takeda, Koji
    Satouchi, Miyako
    Isobe, Hiroshi
    Maemondo, Makoto
    Goto, Koichi
    Hirashima, Tomonori
    Minato, Koichi
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S270 - S271
  • [8] Biomarker analysis from phase I/II study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)
    Gazzah, A.
    Lee, J. S.
    Wang, E.
    Ternes, N.
    Wang, H.
    Boitier, E.
    Lartigau, A.
    Chadjaa, M.
    Dib, C.
    Muzard, G.
    Valence, S.
    Remaury, A.
    Palu, C. C.
    Bauchet, A-L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S81 - S81
  • [9] Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy
    Cho, B. C.
    Aguado de la Rosa, C.
    Vila, L.
    Isla, D.
    Oliveira, J.
    de Castro Carpeno, J.
    Tomova, A.
    Kim, T. M.
    Blasco Cordellat, A.
    Bauchet, A-L.
    Soufflet, C.
    Bensfia, S.
    Dy, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1034 - S1035
  • [10] PHASE II TRIAL OF BEVACIZUMAB PLUS DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Ohyanagi, F.
    Kudo, K.
    Yanagitani, N.
    Horiike, A.
    Horai, T.
    Nishio, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 441 - 442
12345